



**FOR IMMEDIATE RELEASE**  
**PRESS RELEASE**  
November 8, 2006

**PACLITAXEL-ELUTING VASCULAR WRAP FIRST-IN-MAN STUDY TWO YEAR RESULTS**

VANCOUVER, BC, November 8, 2006 –Angiotech Pharmaceuticals, Inc. (NASDAQ: ANPI, TSX: ANP), a global specialty pharmaceutical and medical device company, will host a conference call discussing its paclitaxel-eluting Vascular Wrap First-In-Man Study Two Year results.

Thursday, November 9, 2006 at 10:00 AM ET (7:00 AM PT, 8:00 AM MT, 9:00 AM CT)

Dial information is as follows:

North America (toll-free): (866) 825-3354  
International: (617) 213-8063  
Enter passcode: 17975627

A live webcast, including the slide presentation, will be available to all interested parties through Angiotech's website at [www.angiotech.com](http://www.angiotech.com) under the Investors Relations section. A news release announcing the clinical results will be issued prior to the conference call at approximately 8:00 AM EST (5:00 AM Pacific, 6:00 AM Mountain, 7:00 AM Central).

A replay archive of the conference call will be available until November 16, 2006.

Replay archive information is as follows:

North America (toll-free): (888) 286-8010  
International: (617) 801-6888  
Enter passcode: 99235988

**About Angiotech Pharmaceuticals**

Angiotech Pharmaceuticals, Inc. is a global specialty pharmaceutical and medical device company with 14 facilities in 6 countries and over 1,500 dedicated employees. Angiotech discovers, develops and markets innovative treatment solutions for diseases or complications associated with medical device implants, surgical interventions and acute injury. To find out more about Angiotech Pharmaceuticals, Inc. (NASDAQ: ANPI, TSX: ANP), please visit our website at [www.angiotech.com](http://www.angiotech.com).

Angiotech® is a trademark of Angiotech Pharmaceuticals, Inc. and its subsidiaries. All rights reserved.

**FOR ADDITIONAL INFORMATION**

Analysts and Institutional Investors:  
Deirdre Neary  
Manager, Investor Relations  
Angiotech Pharmaceuticals, Inc.  
(604) 222-7056  
[dneary@angio.com](mailto:dneary@angio.com)

Media and Retail Investors:  
David Scott  
Fleishman-Hillard Canada  
(416) 214-0701  
[david.scott@fleishman.ca](mailto:david.scott@fleishman.ca)